Comprehensive Stock Comparison
Compare Fortress Biotech, Inc. (FBIO) vs Recursion Pharmaceuticals, Inc. (RXRX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | RXRX | 26.9% revenue growth vs FBIO's -31.8% |
| Quality / Margins | FBIO | 6.4% net margin vs RXRX's -8.6% |
| Stability / Safety | FBIO | Beta 0.65 vs RXRX's 2.38 |
| Dividends | FBIO | 1.0% yield; RXRX pays no meaningful dividend |
| Momentum (1Y) | FBIO | +117.8% vs RXRX's -51.1% |
| Efficiency (ROA) | FBIO | 2.2% ROA vs RXRX's -43.7%, ROIC -6.3% vs -95.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Fortress Biotech is a biopharmaceutical company that develops and commercializes pharmaceutical products across multiple therapeutic areas. It generates revenue primarily through sales of its marketed dermatology products — including treatments for acne and skin conditions — supplemented by milestone payments and potential future royalties from its extensive pipeline of late-stage and early-stage drug candidates. The company's key advantage lies in its diversified portfolio approach, which spreads risk across multiple development programs while leveraging partnerships to fund research and development.
Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses an industrialized, technology-driven platform to discover and develop new drugs. It generates revenue primarily through research collaborations and partnerships with pharmaceutical companies — like its major deal with Bayer — while advancing its own pipeline of drug candidates. Its key competitive advantage is its proprietary platform that combines automation, artificial intelligence, and massive biological datasets to systematically decode biology and accelerate drug discovery at scale.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
FBIO leads in 2 of 6 categories (Financial Metrics, Risk & Volatility). RXRX leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
RXRX and FBIO operate at a comparable scale, with $75M and $62M in trailing revenue. FBIO is the more profitable business, keeping 6.4% of every revenue dollar as net income compared to RXRX's -8.6%. On growth, RXRX holds the edge at +6.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FBIOFortress Biotech,… | RXRXRecursion Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $62M | $75M |
| EBITDAEarnings before interest/tax | -$88M | -$564M |
| Net IncomeAfter-tax profit | $4M | -$645M |
| Free Cash FlowCash after capex | -$66M | -$378M |
| Gross MarginGross profit ÷ Revenue | +65.8% | -32.1% |
| Operating MarginEBIT ÷ Revenue | -149.2% | -8.7% |
| Net MarginNet income ÷ Revenue | +6.4% | -8.6% |
| FCF MarginFCF ÷ Revenue | -106.2% | -5.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +20.5% | +6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +114.5% | +60.4% |
Valuation Metrics
| Metric | FBIOFortress Biotech,… | RXRXRecursion Pharmac… |
|---|---|---|
| Market CapShares × price | $95M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $114M | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -1.27x | -2.55x |
| Forward P/EPrice ÷ next-FY EPS est. | 342.00x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.65x | 25.96x |
| Price / BookPrice ÷ Book value/share | — | 1.45x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
FBIO delivers a 6.1% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-57 for RXRX. On the Piotroski fundamental quality scale (0–9), RXRX scores 4/9 vs FBIO's 1/9, reflecting mixed financial health.
| Metric | FBIOFortress Biotech,… | RXRXRecursion Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | +6.1% | -57.0% |
| ROA (TTM)Return on assets | +2.2% | -43.7% |
| ROICReturn on invested capital | -6.3% | -95.8% |
| ROCEReturn on capital employed | -142.0% | -50.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | 0.07x |
| Net DebtTotal debt minus cash | $19M | -$665M |
| Cash & Equiv.Liquid assets | $57M | $743M |
| Total DebtShort + long-term debt | $76M | $78M |
| Interest CoverageEBIT ÷ Interest expense | -4.25x | -491.16x |
Total Returns (with DRIP)
A $10,000 investment in RXRX five years ago would be worth $2,039 today (with dividends reinvested), compared to $588 for FBIO. Over the past 12 months, FBIO leads with a +117.8% total return vs RXRX's -51.1%. The 3-year compound annual growth rate (CAGR) favors RXRX at -23.4% vs FBIO's -33.3% — a key indicator of consistent wealth creation.
| Metric | FBIOFortress Biotech,… | RXRXRecursion Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | -15.1% | -12.6% |
| 1-Year ReturnPast 12 months | +117.8% | -51.1% |
| 3-Year ReturnCumulative with dividends | -70.4% | -55.0% |
| 5-Year ReturnCumulative with dividends | -94.1% | -79.6% |
| 10-Year ReturnCumulative with dividends | -92.0% | -79.6% |
| CAGR (3Y)Annualised 3-year return | -33.3% | -23.4% |
Risk & Volatility
FBIO is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than RXRX's 2.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FBIO currently trades 75.5% from its 52-week high vs RXRX's 46.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FBIOFortress Biotech,… | RXRXRecursion Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.65x | 2.38x |
| 52-Week HighHighest price in past year | $4.53 | $7.89 |
| 52-Week LowLowest price in past year | $1.33 | $2.98 |
| % of 52W HighCurrent price vs 52-week peak | +75.5% | +46.5% |
| RSI (14)Momentum oscillator 0–100 | 51.9 | 46.7 |
| Avg Volume (50D)Average daily shares traded | 729K | 18.2M |
Analyst Outlook
Wall Street rates FBIO as "Buy" and RXRX as "Hold". FBIO is the only dividend payer here at 0.98% yield — a key consideration for income-focused portfolios.
| Metric | FBIOFortress Biotech,… | RXRXRecursion Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | — | $11.00 |
| # AnalystsCovering analysts | 6 | 10 |
| Dividend YieldAnnual dividend ÷ price | +1.0% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.03 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | May 21 | Feb 26 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | 100 | 4.67 | -95.3% |
| Recursion Pharmaceu… (RXRX) | 183.44 | 23.22 | -87.3% |
Recursion Pharmaceu… (RXRX) returned -80% over 5 years vs Fortress Biotech, I… (FBIO)'s -94%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | $16M | $58M | +250.0% |
| Recursion Pharmaceu… (RXRX) | $2M | $75M | +4264.8% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | -3.3% | -79.8% | -2285.5% |
| Recursion Pharmaceu… (RXRX) | -36.5% | -8.6% | +76.4% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | -20.68 | -2.69 | +87.0% |
| Recursion Pharmaceu… (RXRX) | -0.37 | -1.44 | -285.9% |
Chart 5Free Cash Flow — 5 Years
Fortress Biotech, Inc. generated $-95M FCF in 2024 (+28% vs 2021). Recursion Pharmaceuticals, Inc. generated $-378M FCF in 2025 (-91% vs 2021).
FBIO vs RXRX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is FBIO or RXRX a better buy right now?
Analysts rate Fortress Biotech, Inc. (FBIO) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FBIO or RXRX?
Over the past 5 years, Recursion Pharmaceuticals, Inc. (RXRX) delivered a total return of -79.6%, compared to -94.1% for Fortress Biotech, Inc. (FBIO). A $10,000 investment in RXRX five years ago would be worth approximately $2K today (assuming dividends reinvested). Over 10 years, the gap is even starker: RXRX returned -79.6% versus FBIO's -92.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FBIO or RXRX?
By beta (market sensitivity over 5 years), Fortress Biotech, Inc. (FBIO) is the lower-risk stock at 0.65β versus Recursion Pharmaceuticals, Inc.'s 2.38β — meaning RXRX is approximately 267% more volatile than FBIO relative to the S&P 500.
04Which has better profit margins — FBIO or RXRX?
Fortress Biotech, Inc. (FBIO) is the more profitable company, earning -79.8% net margin versus -863.4% for Recursion Pharmaceuticals, Inc. — meaning it keeps -79.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FBIO leads at -191.4% versus -867.9% for RXRX. At the gross margin level — before operating expenses — FBIO leads at 63.8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — FBIO or RXRX?
In this comparison, FBIO (1.0% yield) pays a dividend. RXRX does not pay a meaningful dividend and should not be held primarily for income.
06Is FBIO or RXRX better for a retirement portfolio?
For long-horizon retirement investors, Fortress Biotech, Inc. (FBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), 1.0% yield). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2.38 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FBIO: -92.0%, RXRX: -79.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between FBIO and RXRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. FBIO pays a dividend while RXRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.